Advanced Enzyme Technologies Limited (ADVENZYMES) - Total Assets
Based on the latest financial reports, Advanced Enzyme Technologies Limited (ADVENZYMES) holds total assets worth Rs18.39 Billion INR (≈ $198.86 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ADVENZYMES cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Advanced Enzyme Technologies Limited - Total Assets Trend (2008–2026)
This chart illustrates how Advanced Enzyme Technologies Limited's total assets have evolved over time, based on quarterly financial data. Explore ADVENZYMES long-term investment intensity to see how much of total assets are deployed in long-term investments.
Advanced Enzyme Technologies Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Advanced Enzyme Technologies Limited's total assets of Rs18.39 Billion consist of 56.8% current assets and 43.3% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 6.3% |
| Accounts Receivable | Rs1.45 Billion | 7.9% |
| Inventory | Rs1.77 Billion | 9.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs469.22 Million | 2.6% |
| Goodwill | Rs3.69 Billion | 20.1% |
Asset Composition Trend (2008–2026)
This chart illustrates how Advanced Enzyme Technologies Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Advanced Enzyme Technologies Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Advanced Enzyme Technologies Limited's current assets represent 56.8% of total assets in 2026, an increase from 40.4% in 2008.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2026, up from 0.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 20.1% of total assets.
Advanced Enzyme Technologies Limited Competitors by Total Assets
Key competitors of Advanced Enzyme Technologies Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Linde plc Ordinary Shares
NASDAQ:LIN
|
USA | $86.82 Billion |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
China | CN¥10.25 Billion |
|
Ningbo Shanshan Co Ltd
SHG:600884
|
China | CN¥45.88 Billion |
|
Incitec Pivot Ltd
AU:IPL
|
Australia | AU$8.40 Billion |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥6.27 Billion |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
China | CN¥89.26 Billion |
|
Zhejiang Transfar Co Ltd
SHE:002010
|
China | CN¥38.45 Billion |
|
Aarti Industries Limited
NSE:AARTIIND
|
India | Rs132.99 Billion |
Advanced Enzyme Technologies Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.78 | 9.09 | 7.64 |
| Quick Ratio | 8.12 | 7.47 | 6.25 |
| Cash Ratio | 0.00 | 1.11 | 0.00 |
| Working Capital | Rs9.37 Billion | Rs7.83 Billion | Rs4.49 Billion |
Advanced Enzyme Technologies Limited - Advanced Valuation Insights
This section examines the relationship between Advanced Enzyme Technologies Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.55 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 13.4% |
| Total Assets | Rs18.39 Billion |
| Market Capitalization | $452.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Advanced Enzyme Technologies Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Advanced Enzyme Technologies Limited's assets grew by 13.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Advanced Enzyme Technologies Limited (2008–2026)
The table below shows the annual total assets of Advanced Enzyme Technologies Limited from 2008 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs18.39 Billion ≈ $198.86 Million |
+13.41% |
| 2025-03-31 | Rs16.21 Billion ≈ $175.34 Million |
+5.59% |
| 2024-03-31 | Rs15.35 Billion ≈ $166.05 Million |
+7.99% |
| 2023-03-31 | Rs14.22 Billion ≈ $153.77 Million |
+12.17% |
| 2022-03-31 | Rs12.68 Billion ≈ $137.09 Million |
+9.97% |
| 2021-03-31 | Rs11.53 Billion ≈ $124.66 Million |
+17.79% |
| 2020-03-31 | Rs9.79 Billion ≈ $105.83 Million |
+20.65% |
| 2019-03-31 | Rs8.11 Billion ≈ $87.72 Million |
+10.86% |
| 2018-03-31 | Rs7.32 Billion ≈ $79.12 Million |
+26.90% |
| 2017-03-31 | Rs5.77 Billion ≈ $62.35 Million |
+27.98% |
| 2016-03-31 | Rs4.51 Billion ≈ $48.72 Million |
+8.32% |
| 2015-03-31 | Rs4.16 Billion ≈ $44.98 Million |
+2.42% |
| 2014-03-31 | Rs4.06 Billion ≈ $43.92 Million |
+2.54% |
| 2013-03-31 | Rs3.96 Billion ≈ $42.83 Million |
+13.36% |
| 2012-03-31 | Rs3.49 Billion ≈ $37.78 Million |
+126.89% |
| 2011-03-31 | Rs1.54 Billion ≈ $16.65 Million |
+41.17% |
| 2010-03-31 | Rs1.09 Billion ≈ $11.80 Million |
+15.98% |
| 2009-03-31 | Rs940.41 Million ≈ $10.17 Million |
+3.74% |
| 2008-03-31 | Rs906.55 Million ≈ $9.80 Million |
-- |
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing … Read more